ACR appropriateness criteria post-treatment follow-Up of renal cell carcinoma

David D. Casalino, Erick M. Remer, Jay T. Bishoff, Courtney A. Coursey, Manjiri Dighe, Howard J. Harvin, Marta E. Heilbrun, Massoud Majd, Paul Nikolaidis, Glenn M. Preminger, Steven S. Raman, Sheila Sheth, Raghunandan Vikram, Robert M. Weinfeld

Research output: Contribution to journalArticlepeer-review


Although localized renal cell carcinoma can be effectively treated by surgery or ablative therapies, local or distant metastatic recurrence after treatment is not uncommon. Because recurrent disease can be effectively treated, patient surveillance after treatment of renal cell carcinoma is very important. Surveillance protocols are generally based on the primary tumor's size, stage, and nuclear grade at the time of resection, as well as patterns of tumor recurrence, including where and when metastases occur. Various imaging modalities may be used in the evaluation of these patients. Literature on the indications and usefulness of these radiologic studies is reviewed. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)443-449
Number of pages7
JournalJournal of the American College of Radiology
Issue number5
StatePublished - May 2014


  • Appropriateness Criteria
  • ablation
  • follow-up
  • imaging
  • kidney cancer
  • renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'ACR appropriateness criteria post-treatment follow-Up of renal cell carcinoma'. Together they form a unique fingerprint.

Cite this